公司股东天狼星控股集团有限公司质押 5,500,000 股，占公司总股本 1.96%。 在本次质押的股份中，5,500,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2026 年 1 月 12 日起至业务结清止。质押股份用于为公司银行授信提 供担保，质押权人为兴业银行股份有限公司北京大兴支行，质押权人与质押股东 不存在关联关系。质押股份已在中国结算办理质押登记。 证券代码：920575 证券简称：康乐卫士 公告编号：2026-005 北京康乐卫士生物技术股份有限公司 股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、股权质押概述 （一）基本情况 公司股东天狼星控股集团有限公司质押 10,000,000 股，占公司总股本 3.56%。 在本次质押的股份中，10,000,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2026 年 1 月 8 日起至业务结清止。质押股份用于为公司银行授信提 供担保，质押权人为北京银行股份有限公司北京经济技术开发区分行， ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-003 北京康乐卫士生物技术股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 1 月 12 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯相结合的方式 4.发出董事会会议通知的时间和方式：2026 年 1 月 8 日以邮件和电话方式发 出 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于接受关联方担保暨关联交易的议案》 1.议案内容： 为满足北京康乐卫士生物技术股份有限公司（以下简称"公司"）日常生产 经营及业务开展的需要，推动公司持续发展，公司控股股东天狼星控股集团有限 公司（以下简称"天狼星集团"）为公司与上海斯丹姆医药开发有限责任公司前 期签署的临床试验相关合同项下 41,156,462.22 元费用提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先 ...

每经讯，2026年1月13日，北交所上市公司康乐卫士（920575，收盘价：11.99元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日收盘价涨幅达到29.90%，成交数量3511.98万股，成交金额4.02亿元。买一席位为甬兴证券有限公司宁波和源路证券营业 部，买入1768.5万元；卖一席位为国金证券股份有限公司成都武成大街证券营业部，卖出2759.29万元。 | | 2026-01-13康乐卫士 (920575) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | न्द्र ग | 用兴证券有限公司宁波和源路证券营业部 | 17684998.21 | 0 | | 址2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 10787525 | 11314658.06 | | ग्रें3 | 东方证券股份有限公司昆明白龙路证券营业部 | 9962715.23 | 0 | | 买4 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 8461071.27 | 0 | | ન્નેર | 华安证券股份有 ...

从资金流向上来看，当日生物制品板块主力资金净流入3.99亿元，游资资金净流出6286.66万元，散户资 金净流出3.36亿元。生物制品板块个股资金流向见下表： 证券之星消息，1月13日生物制品板块较上一交易日上涨1.15%，康乐卫士领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920575 | 康乐卫士 | 11.99 | 29.90% | 35.12万 | | 4.02亿 | | 688331 | 荣昌生物 | 114.46 | 20.00% | 21.22万 | | 23.69亿 | | 688137 | 沂岸蛋白 | 49.60 | 15.43% | 5.81万 | | 2.91亿 | | 920344 | 三元基因 | 28.45 | 11.44% | 6.86万 | | 1.94亿 | | 301047 | 义翘神州 | 82.02 | ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-001 北京康乐卫士生物技术股份有限公司 关于公司银行授信暨关联交易公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 在上述授权期限内，融资授信额度可循环使用，在不超过融资授信额度及担 保额度的情况下，上述申请事项具体实施无需再逐项提请董事会及股东会审批。 公司将按照相关规定，根据上述融资担保事项实际情况和协议内容及时履行信息 披露义务。 1、为满足业务发展需要，北京康乐卫士生物技术股份有限公司（以下简称 "公司"）向北京银行申请不超过壹亿元（含壹亿元）综合授信额度，用于贷款、 承兑汇票、保函等业务融通使用，期限肆年，担保方式为由公司控股股东天狼星 控股集团有限公司（以下简称"天狼星集团"），公司实际控制人陶涛夫妇，公司 时任董事长、法定代表人郝春利夫妇，公司时任董事、总经理刘永江夫妇提供连 带责任保证担保。根据最终签署的授信合同，上述银行授信最高授信额度为捌仟 万元整，担保方式为由公司控股股东天狼 ...

Market Overview - In 2025, the A-share market experienced a structural "small bull" market, with 4,110 out of 5,176 stocks showing positive growth, and 523 stocks rising over 100% [1] - However, 40 stocks fell over 30%, with 7 stocks declining more than 40% [1] Worst Performing Stocks - The largest decline was seen in Shijing Technology, which dropped 50.99% in 2025, primarily due to a significant decrease in completed orders after entering the photovoltaic sector [3] - Kangle Weishi ranked second with a decline of 49.97%, continuing to face losses since 2013, with a net profit loss of 2.29 billion yuan in the first three quarters of 2025 [3][4] - Longda Meishi experienced a 48.11% drop, affected by a prolonged downturn in the pig cycle and intensified competition in the prepared food sector [3] Financial Performance - Kangle Weishi reported a revenue of 1.2763 million yuan in the first three quarters of 2025, a year-on-year increase of 106.53%, but still faced a net profit loss of 2.29 billion yuan [4] - The food and beverage sector saw a 9.69% decline in 2025, marking its fifth consecutive year of losses, with a cumulative drop of over 50% since the peak in 2021 [8][10] Industry Trends - The pharmaceutical and biotechnology sector showed signs of recovery in 2025, with an 11.94% increase, ending a four-year downtrend [10] - The food and beverage sector is expected to benefit from macro policies aimed at boosting domestic demand, with potential recovery in the white liquor and pre-processed food segments [10][11]

Group 1 - The stock of Kang Le Wei Shi (920575.BJ) closed at 8.27 yuan, with a decline of 4.83%, currently in a state of breaking issue [1] - Kang Le Wei Shi was listed on the Beijing Stock Exchange on March 15, 2023, with an initial offering price of 42.00 yuan, and the stock closed at 35.52 yuan on its first day, a drop of 15.43% [1] - The company issued 7,000,000 shares (excluding the overallotment option) and 8,050,000 shares (if the overallotment option is fully exercised) [1] Group 2 - The total amount of funds raised by Kang Le Wei Shi before the exercise of the overallotment option was 29,400,000 yuan, with a net amount of 26,662,410 yuan after deducting issuance costs of 2,737,590 yuan (excluding VAT) [1] - The net amount raised was 3,337,590 yuan less than the original plan of 30,000,000 yuan, which was intended for HPV vaccine research and the construction of a production base in Kunming [1] - The total issuance costs were 2,737,590 yuan (before the exercise of the overallotment option) and 3,008,020 yuan (if the overallotment option is fully exercised) [2] Group 3 - On May 17, 2023, Kang Le Wei Shi announced a dividend plan of 10 shares for every 10 shares, with the ex-dividend date set for May 26, 2023 [3]

Core Viewpoint - The company Kang Le Wei Zhi is facing significant liquidity pressure due to ongoing R&D investments and delays in financing, leading to multiple court-ordered consumption restrictions and frozen bank accounts [2][3][4]. Financial Situation - As of December 26, 2025, Kang Le Wei Zhi's total market capitalization was 2.512 billion yuan [2]. - The company reported a net loss of 3.57 billion yuan for the year 2024, with a net asset deficit of 1.686 billion yuan [8]. - By the end of 2024, the company's current liabilities exceeded current assets by 7.32 billion yuan [8]. - For the first three quarters of 2025, the company generated revenue of 127.63 million yuan, with a net loss of 2.29 billion yuan [9]. Legal and Operational Challenges - The company and its legal representative, Tao Ran, have been subjected to multiple consumption restriction orders due to failure to fulfill financial obligations, with amounts involved totaling 19.85 million yuan, 6.6 million yuan, and 7.86 million yuan [3][4]. - As of December 18, 2025, 15 bank accounts belonging to the company and its subsidiaries were frozen, representing 41.67% of their total accounts, with a cumulative frozen amount of 346,900 yuan [5]. R&D and Market Position - Kang Le Wei Zhi specializes in HPV vaccines, with ongoing clinical trials for various products, including a nine-valent HPV vaccine and a fifteen-valent HPV vaccine in collaboration with Chengda Biological [6]. - The HPV vaccine market is highly competitive, with several established players and a decline in vaccine prices due to increased supply [7]. - The company has not yet launched any vaccine products, and its revenue primarily comes from the sale of research reagents, which is relatively small [7]. Future Outlook - The company has submitted an application for a Hong Kong stock listing, but there has been no recent progress [6]. - The inclusion of HPV vaccines in the national immunization program starting November 10, 2025, may intensify competition for Kang Le Wei Zhi's products [7].

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

Core Viewpoint - Beijing Kanglwei Biological Technology Co., Ltd. (Kanglwei) announced that its subsidiary, Kunming Kanglwei, failed to repay a loan of 15.21 million yuan from CITIC Bank but has since settled the debt in full [1] Financial Performance - As of September 2025, Kanglwei's consolidated asset-liability ratio was approximately 78.36%, an increase of 14.16% from 64.20% at the end of 2024 [1] - Current non-current liabilities due within one year amounted to approximately 96.49 million yuan, reflecting a change of 64.75% [1] - Long-term borrowings were approximately 17.28 million yuan, showing a decrease of 81.06% [1] - Lease liabilities were approximately 0.29 million yuan, with a change of -90.91% [1] Company Overview - Established in 2008, Kanglwei is a high-tech enterprise focused on innovative vaccine research and commercialization [2] - The company is a leader in HPV vaccine development in China, offering a comprehensive product portfolio that includes three-valent, nine-valent, and fifteen-valent HPV vaccines [2] - As of September, Kanglwei's R&D expenses accounted for approximately 9263.76% of total operating income, the highest among companies listed on the Beijing Stock Exchange [2]